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Abstract: The interplay between the dopamine (DA) and opioid systems in the brain is known to 
modulate the additive effects of substances of abuse. On one hand, opioids serve mankind by their 
analgesic properties, which are mediated via the mu opioid receptor (MOR), a Class A G protein-
coupled receptor (GPCR), but on the other hand, they pose a potential threat by causing undesired 
side effects such as tolerance and dependence, for which the exact molecular mechanism is still 
unknown. Using human embryonic kidney 293T (HEK 293T) and HeLa cells transfected with MOR 
and the dopamine D2 receptor (D2R), we demonstrate that these receptors heterodimerize, using an 
array of biochemical and biophysical techniques such as coimmunoprecipitation (co-IP), 
bioluminescence resonance energy transfer (BRET1), Fӧrster resonance energy transfer (FRET), and 
functional complementation of a split luciferase. Furthermore, live cell imaging revealed that D2LR, 
when coexpressed with MOR, slowed down internalization of MOR, following activation with the 
MOR agonist [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO). 




For hundreds of years, opioids have been used in the management of pain, mediating their 
analgesic effect primarily via binding to the mu opioid receptor (MOR) [1–3]. Dependence and rapid 
development of tolerance limit the long-term use of opioids [4]. MOR, a member of the Class A G 
protein-coupled receptor (GPCR) subfamily, is activated by both endogenous opioid peptides as well 
as exogenous opioids [5]. The latter constitute the potent analgesics, which carry the risk of being 
used as substances of abuse [6,7]. Although the mechanism of tolerance, defined as the decline in 
effect of a drug due to its chronic exposure, is not known exactly, it has been linked to receptor 
desensitization and recruitment of β-arrestin in vivo [8–12]. GPCR kinases (GRKs) phosphorylate the 
activated receptors, which in turn recruit β-arrestin 1 and β-arrestin 2, and the docking of these 
proteins shuts off the signal through the G proteins, ultimately resulting in receptor endocytosis 
[13,14]. In contrast, there are numerous studies that demonstrated that in highly tolerant animals, 
there was no change in expression of MOR in response to morphine, but this observation has been 
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argued to depend on the dosage, route, and model organism [9,15]. Thus, it could be postulated that 
there may be other, or a combination of, mechanisms that could affect receptor desensitization and 
downregulation.  
The dopamine receptor (D2R), also a member of the Class A GPCR subfamily, signals upon 
binding of its catecholamine neurotransmitter, dopamine. Like MOR, D2R is also coupled to the Gi/o 
subunit that inhibits adenylyl cyclase and decreases the production of the second messenger cyclic 
adenosine monophosphate (cAMP ) [16,17]. D2R also causes intracellular Ca+2 release through the 
Gβγ subunits [17]. Several in vitro studies have shown that dopamine receptors undergo 
phosphorylation by GRKs and recruit β-arrestins in response to agonists, similar to other GPCRs 
[14,17].  
Interactions between the opioid and dopamine receptor systems have been shown in several 
regions of the brain, such as the ventral tegmental area (VTA) and the nucleus accumbens (NAc), 
which is associated with the reward system and the addictive behavior of drugs [18,19]. Rivera et al. 
[20] have shown that continuous treatment with morphine caused morphological changes in nigral 
dopamine nerve cells, which was restored by cotreatment with the dopamine D4 receptor (D4R) 
agonist, PD 168,077. Additionally, it was observed that morphine increased locomotion in mice, 
which was counteracted by the coadministration of PD 168,077. Using a condition place preference 
paradigm, activation of D4R accompanying the administration of morphine was found to decrease 
the rewarding affects associated with morphine and to attenuate the development of physical 
dependence associated with morphine. Importantly, the analgesic properties of morphine remained 
unaltered [20]. A recent study by Dai et al. [21], demonstrated that levo-corydalmine (l-CDL), a 
traditional herb used in China to alleviate pain, when coadministered with morphine, attenuated 
morphine tolerance in mice. l-CDL acted as an antagonist of D2R and the inhibition of tolerance 
demonstrated by this compound was reversed upon addition of quinpirole, a D2R agonist. Using 
several pain models in the rat, Mercado-Reyes et al. [22], reported an enhanced antinociceptive effect 
of the MOR agonist [D-Ala2, N-MePhe4, Gly-ol]-enkephalin DAMGO, when coadministered with 
quinpirole. 
There is substantial evidence for the existence of GPCR dimers, oligomers, and even higher order 
oligomers. Also, literature suggests a role for heteromerization in modulating receptor functions. 
Further, D2R [23,24] and MOR not only homodimerize [25], but also form heteromers with many 
other GPCRs. D2R has been reported to heterodimerize with the adenosine A2A [26,27], serotonin 
5HT2A [28], and cannabinoid CB1 receptor [29,30] whilst MOR heterodimerization with delta opioid 
receptor (DOR) [31] and cholecystokinin B receptor (CCKBR) [32] has been described. The dopamine 
D4 receptor (D4R) has been shown to form heterodimers with both D2R and MOR [33,34]. The 
formation of these heteromers may have an important role in modulating the signaling pathways of 
the interacting partners, in addition to potentially modifying ligand binding to the receptors. In a 
study by Dai et al. [35], it was demonstrated that MOR colocalized with D2R in the spinal cords of 
mice and this finding was also confirmed by coimmunoprecipitation. Chronic morphine treatment 
caused an increase in interaction between the heterodimer, while administration of sulpiride, a D2R 
antagonist, disrupted the interaction between MOR and D2R, which led to the attenuation of 
morphine tolerance, indicating that increased interaction between MOR–D2R could have a role in the 
development of chronic morphine tolerance. 
In the present study, we have applied a wide array of complementary techniques, including 
coimmunopreciptation, bioluminescence resonance energy transfer (BRET1), functional 
complementation (NanoBiT®), and Förster resonance energy transfer (FRET) to demonstrate the 
heterodimerization between MOR and D2R. Furthermore, using live cell imaging we observed that 
the internalization of MOR, when stimulated with its agonist DAMGO, is slowed down in the 
presence of D2R. 
2. Materials and Methods  
2.1. Reagents and Antibodies 
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DAMGO was purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s Modified Eagle 
medium (DMEM), penicillin/streptomycin, glutamine, Trypsin-EDTA (0.05%), Hank’s Balanced Salt 
Solution (HBSS), Phusion High-Fidelity (HF) PCR Master Mix with HF buffer, Turbofect™ (a 
transient mammalian cell transfection reagent), Protein A Trisacryl beads, Pierce™ Bicinchoninic acid 
assay (BCA) Protein Assay Kit, Fluo-4 AM (F14201), and T4 DNA ligase were purchased from Thermo 
Fisher Scientific (Pittsburg, PA, USA). Fetal bovine serum (FBS) was purchased from Biochrom, 
which is a now a part of Merck (Merck KGaA, Darmstadt, Germany). Phosphate buffered saline (PBS) 
was purchased from Lonza (Lonza Walkersville, US). Polyethylenimine (PEI) (a transient mammalian 
cell transfection reagent), carbenicillin, and Tween 20 were procured from Sigma-Aldrich (Steinheim, 
Germany). The Nano-Glo® Live Cell reagent was purchased from Promega (Madison, WI, USA). h-
coelenterazine was procured from Molecular Probes (Eugene, OR, USA). Primers were synthesized 
by Eurofins Genomics (Ebersberg, Germany). Restriction enzymes HindIII, EcoRI, and XhoI were 
from New England Biolabs (NEB, Massachusetts, USA). Blocking buffer was purchased from LI-COR 
Biosciences (Lincoln, NE, USA). The antibodies used were: Mouse anti-haemagglutinin (HA) tag 
(anti-HA16B12) (MMS-101P-1000) from Covance (Princeton, NJ, USA) for co-IP, mouse anti-FLAG® 
M2 (F3165) from Sigma-Aldrich for co-IP, rabbit anti-GFP (G1544) from Sigma, rabbit anti-HA 
(GTX29110) from Gene TEX (Irvine, CA, USA), rabbit anti-D2R (RRID:AB_2571596) from Frontier 
Institute (Hokkaido, Japan), goat anti-rabbit IRDye680RD (926-68071), and goat anti-rabbit 
IRDye800CW (926-32211) from LI-COR Biosciences (Lincoln, NE, USA). 
2.2. Construction of Plasmids 
pHA-D2LR was purchased from UMR cDNA Resource Center (www.cdna.org). The plasmid 
pMOR-RLuc was a kind gift from Dr. Francisco Ciruela (University of Barcelona, Barcelona, Spain), 
pD2LR-mCherry was a kind gift from Dr. Ibeth Guevara-Lora (Jagiellonian University, Krakow, 
Poland), and pmCherry-CAAX was from Dr. Deepak Saini’s laboratory (Indian Institute of Science, 
Bangalore, India). The plasmids pMOR-YFP, pFLAG-D2SR, pD2LR-YFP, pD2LR-RLuc, and pEYFP were 
kindly provided by Dr. Kjell Fuxe (Karolinska Institutet, Stockholm, Sweden). The plasmid pEGFP 
was procured from Clontech Laboratories (Saint-Germain-en-Laye, France). The sequences encoding 
human D2LR and MOR were amplified using the primers described in Table S1 using an MJ Research 
PTC-200 Thermal Cycler (GMI, MN, USA) and cloned in the NanoBiT® system from Promega 
(Madison, WI, USA). Using this system, the split fragments of nanoluciferase, namely LargeBiT 
(LgBiT, an 18kD protein) and SmallBiT (SmBiT, an 1kD peptide) were fused C-terminally to the D2LR 
and MOR. HaloTag-SmBiT was also procured from Promega. D2LR-EGFP was constructed by 
digestion of D2LR-LgBiT with HindIII and EcoRI and subcloning into the pEGFP-N3 vector (Addgene, 
Watertown, MA, USA). The constructs containing the appropriate inserts were verified by restriction 
digest and by sequencing. 
2.3. Cell Culture and Transfection 
HEK 293T (American Type Culture Collection (ATCC), Manassas, VA, USA) cells were used for 
all heterodimerization studies by co-IP, BRET1, and NanoBiT®. The cells were cultured in DMEM 
supplemented with 10% heat inactivated FBS, 2 mM glutamine, 100 IU/mL penicillin, and 100 µg/mL 
streptomycin and maintained at 37 °C in a humidified atmosphere with 5% CO2. For the experiments 
involving fluorescence microscopy, a human cervical cancer cell line (HeLa) (ATCC, Manassas, VA, 
USA), maintained under the same conditions as mentioned above, was used. The cells were 
transiently transfected with relevant plasmids using PEI [36] (co-IP, BRET1, NanoBiT®), or with 
Turbofect™ (for imaging studies) and cultured for 48 h. 
2.4. Coimmunoprecipitation 
Cells expressing HA-D2LR (or FLAG-D2SR) with and without MOR-YFP from a semiconfluent 10 
cm2 dish, were washed with cold PBS 48 h posttransfection, collected, and frozen at −70 °C prior to 
adding 300 µl of RIPA buffer (250 mM NaCl; 50 mM Tris/HCl pH 7.5; 1% Nonidet P-40 (NP-40); 0.1% 
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sodium-dodecyl sulfate (SDS), 0.5% deoxycholic acid (fresh) supplemented with protease and 
phosphatase inhibitors (2.5 µg/mL aprotinin, 1 mM Pefa-block, 10 µg/mL leupeptin, 10 mM β-
glycerolphosphate), and mixed at 4 °C for 1 h. An aliquot of the lysate was denatured at 37 °C for 10 
min in SDS-sample buffer (4% SDS; 50% glycerol; 0.2% bromophenol blue; 65 mM Tris/HCl pH 6.8 
and 50 mM dithiothreitol) and loaded on a 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
gel to check the expression of the proteins. The rest of the lysate was incubated with 2 µg of primary 
antibody (mouse anti-HA16B12 or mouse anti-FLAG®M2), while rotating at 4 °C for 4 h. To this, 20 
µl of Protein A Trisacryl beads were added and incubated overnight at 4 °C. Subsequently, the sample 
containing beads was washed three times with RIPA buffer (with inhibitors), denatured at 37 °C for 
10 min in SDS-sample buffer, and separated on a 10% SDS-PAGE gel. The separated proteins were 
transferred onto a nitrocellulose membrane, which was blocked using blocking buffer prior to 
incubation with the following antibodies, prepared in blocking buffer with TBS (1:1) containing 0.1% 
Tween 20 (TBS-T): Rabbit anti-HA, anti-GFP, and rabbit anti-D2R. Following three washes with TBS-
T for 3 times, the blots were incubated with secondary antibodies—goat anti-rabbit antibody coupled 
with IRDye680RD or goat anti-rabbit antibody coupled with IRDye800CW for 1 h. After 1 h, the blots 
were washed with TBS-T and imaged with the Odyssey® Infrared Imaging system (IGDR, Rennes, 
France). 
2.5. Bioluminescence Resonance Energy Transfer1 (BRET1) 
HEK 293T cells growing on a 6-well plate were transiently transfected with a fixed concentration 
of donor plasmid (pMOR-RLuc or pD2LR-RLuc) and increasing concentrations of acceptor plasmid 
(pD2LR-YFP or pMOR-YFP or pEYFP), respectively. Then, 48 h post-transfection, the cells were 
washed twice with warm PBS, detached, centrifuged at 1000× g for 10 min, and resuspended in HBSS. 
An aliquot was used for protein estimation by BCA assay. The cell suspension with a corresponding 
protein concentration of 600 ng/µL was distributed in duplicate into a black or white 96-well 
microplate for fluorescence and luminescence measurements, respectively. For luminescence, h-
coelenterazine at a final concentration of 5 µM was added and measurements were done using a 
microplate reader, Clariostar (BMG LABTECH, Cary, NC, USA), which allows sequential integration 
of signals detected at 480 (± 20) nm (luciferase) and 530 (± 20) nm (YFP). The BRET1 ratio is expressed 
as a ratio of the light intensity at 530 nm over the light intensity at 480 nm and is corrected by 
subtracting the background ratio observed in cells transfected with RLuc-tagged receptor alone. 
2.6. Functional Complementation Assay Using Split Luciferase 
HEK 293T cells growing on a 10 cm2 dish were transiently transfected with plasmids encoding 
D2LR-LgBiT in combination with MOR-SmBiT or HaloTag-SmBiT, or with MOR-LgBiT in 
combination with D2LR-SmBiT or HaloTag-SmBiT, along with a constant amount of a plasmid 
encoding enhanced green fluorescent protein (EGFP). Then, 48 h post-transfection, cells were washed 
twice with warm PBS, detached, centrifuged at 1000× g for 10 min, and subsequently suspended in 
HBSS. Protein estimation was performed on an aliquot using BCA assay. The cell suspensions were 
diluted to bring all of them to a density corresponding with a protein concentration of 600 ng/µL. 
Next, 25 µL of Nano-Glo® Live cell reagent containing furimazine substrate (20× diluted using Nano-
Glo® LCS dilution buffer) was added to 100 µL of cell suspension, which was added to a 96-well white 
plate, and the luminescence was measured using the ClarioSTAR. Fluorescence measurements were 
carried out in a black 96-well plate. The luminescence data in all conditions were normalized to their 
respective fluorescence signals. 
2.7. Fӧrster Resonance Energy Transfer (FRET) 
HeLa cells growing on a 6-well plate were transiently transfected with plasmids encoding MOR-
YFP, combined with either D2LR-mCherry or mCherry-CAAX. Then, 48 h post-transfection, the cells 
were washed with warm PBS, detached and resuspended in HBSS, and an equal number of cells were 
distributed into a black 96-well plate (Corning Inc., Corning, NY, USA). The fluorescence intensities 
Biomolecules 2019, 9, 368 5 of 16 
were recorded in the donor–donor (DD) channel (donor excitation 514/10 nm, donor emission 527/10 
nm) and donor–acceptor (DA) channel (donor excitation 514/10 nm, acceptor emission 587/10) using 
a bottom recording mode in a multimode fluorescence plate reader (Infinite M1000 PRO, Tecan, 
Austria). The FRET ratio was expressed as a ratio of light intensity in the FRET channel DA divided 
by light intensity in the donor–donor channel, DD. 
2.8. Fluorescence Recovery After Photobleaching (FRAP) 
FRAP experiments were performed by bleaching a region of interest (ROI) on the plasma 
membrane using a 488 nm laser set at 100% power with the help of 3i vector system (3i Inc., Denver, 
CO, USA) on an Olympus IX83 epifluorescence microscope (Olympus, Shinjuku, Japan), connected 
to a SpectraX fluorescent light source and cascade II EMCCD camera, and controlled using Slidebook 
6 software (Intelligent Imaging Innovations, Inc., Denver, CO, USA). Fluorescence recovery was 
monitored by time lapse imaging in the YFP channel for a total duration of 9 min, with an interval of 
10 s between two successive frames. At the 5th frame (i.e., at the 50th second from initial time point 
0), the ROIs were photobleached and subsequently, the recovery was measured as described above. 
FRAP kinetics were calculated as follows: The first step was to normalize the intensity at all time 
points (It) to the intensity at the first time point of imaging (I0, at t = 0 s), thus yielding It/I0. In the next 
step, the intensity at the bleaching time point was subtracted from all the time points, such that the 
intensity at the time of bleaching was 0 (Ib). Then, the relative intensities of the individual cells 
(approximately 50 cells) under each condition (with and without coexpression of D2LR) were plotted 
as a function of time using Graph Pad prism to yield t1/2, which is the time required for half maximal 
recovery after photobleaching. 
2.9. Fluorescence Live cell Imaging 
HeLa cells growing on a 35 mm glass bottom dish (NEST, Wuxi, China) were transfected with 
the relevant plasmids and 48 h post-transfection the cells were washed with HBSS containing 10 mM 
HEPES (pH 7.0) and replaced with HBSS with (for internalization assay) or without calcium (for 
calcium measurements) for imaging. The fluorescence imaging was performed using an inverted 
epifluorescence microscope Olympus IX83, equipped with Lumencor Spectra X light engine 
(Lumencor, Beaverton, OR, USA) and band pass filters in a high-speed filter wheel (ASI Inc., Eugene, 
OR, USA). The images were acquired using a Cascade II EM-CCD camera (Photometrics Inc., 
Pittsfield, MA, USA) under controlled temperature and using a CO2 incubation system (Okolab, 
Pozzuoli, Italy). The devices were controlled by Slidebook 6 software, which was also used for data 
acquisition and analysis. 
2.9.1. Measurement of Calcium Release Using Fluo-4 AM by Live Cell Imaging 
In cells growing in glass-bottom dishes, the medium was replaced with DMEM (without FBS) 
containing 1 µM of the calcium binding dye Fluo-4 AM, followed by incubation for 45 min at 37 °C 
and 5% CO2. Next, the cells were washed with calcium free HBSS and imaged in HBSS for 10 min 
using a 20× objective with a 10 s interval between each image. The ligand was added at the 5th frame 
(10 s/frame) using a syringe pump.  
2.9.2. Internalization Assay by Live Cell Imaging 
Following replacement of the medium with HBSS, images were acquired using a plan-
apochromat 60×/1.35 oil-immersion lens, with time lapse imaging. The agonist DAMGO/vehicle was 
added at the 10th frame (10 s/frame) and cells were monitored for 1 h. All the images were processed 
by ImageJ software (NIH, Bethesda, MD, USA). Cytosolic intensity was measured by drawing a ROI 
in each cell, normalized to the basal (unstimulated) condition, and plotted as a function of time. 
2.10. Statistical Analysis 
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For all the experiments, n represents independent biological replicates and the data depicted are 
mean ± standard deviation (SD), unless when mentioned otherwise. The p values were calculated 
using student’s t-test with two-tailed distribution. 
3. Results 
3.1. Coimmunoprecipitation Indicates that MOR and D2R Heterodimerize in Transfected HEK 293T Cells 
HEK 293T cells were transiently transfected with plasmids encoding HA-tagged D2LR and/or 
MOR-YFP. Receptor expression was confirmed in total lysates (lanes 5–8 of Figure 1A,B). The 
presence of HA-D2LR in lane 2 of Figure 1B also confirmed that the immunoprecipitation was 
successful. Immunoprecipitation with anti-HA antibody of HA-tagged D2LR in cotransfected HEK 
293T cells resulted in the precipitation of YFP-tagged MOR, which was detected using an anti-GFP 
antibody (lane 4 of Figure 1A). The appearance of bands at a higher molecular weight than predicted 
indicates the presence of dimers or higher order oligomers that are resistant to denaturation by SDS 
and may involve hydrophobic interactions [36,37]. As a control, lysates of cells that had been 
transfected with individual receptors alone were mixed and processed as per the protocol. The lack 
of co-IP in this experiment confirmed the specificity of the interaction, as well as confirmed that it 
happens in the same cell only (Figure S1). To gain some insight into the interaction sites, co-IP was 
also performed with the short isoform of D2R (D2SR) in a similar way as described above. This is a 
splice variant of D2R lacking a stretch of 29 amino acids in the ICL3 of D2LR. Co-IP results indicate 
that MOR can heterodimerize with D2SR as well, thus proving that the interaction sites for the dimer 
do not lie in the stretch of 29 amino acids of ICL3, unlike reported for D1R-D2R heterodimers [38] 
(Figure S1). 
 
Figure 1. Assessment of D2R receptor dimerization with mu opioid receptor (MOR) using 
coimmunoprecipitation. HEK 293T cells were transiently transfected with pHA-D2LR, pMOR-YFP, or 
both. After 48 h, the cells were lysed, and an aliquot of the lysates was subjected to SDS-PAGE 
followed by immunoblotting with anti-HA or anti-GFP. The rest of the lysates was subjected to 
immunoprecipitation (IP) with anti-HA. Coimmunoprecipitation of D2LR and MOR was detected by 
immunoblotting with anti-GFP (A) and anti-HA (B). 
3.2. Fluorescently Tagged D2LR and MOR are Functionally Expressed on the Plasma Membrane of Hela Cells 
Following the demonstration of co-IP, we next wanted to study D2LR–MOR heteromerization in 
living cells, for which we generated fluorescent and luminescent protein-tagged receptors, which 
could be used to study the interaction either by FRET, BRET, NanoBiT®, or live cell imaging. We first 
validated the functionality and localization of these tagged receptors. To determine whether the 
fluorescent protein tag affected the plasma membrane localization of D2LR or MOR, HeLa cells 
transfected with MOR-YFP or D2LR-mCherry were analyzed using fluorescence microscopy. In both 
instances, fluorescent YFP or mCherry signals were primarily present at the plasma membrane, 
although for D2LR, a small fraction was observed intracellularly, likely corresponding to the 
endoplasmic reticulum, from where this receptor traffics (Figure 2). Functionality of the tagged 
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receptors was next evaluated by monitoring their capacity to internalize or stimulate calcium release 
upon stimulation with their respective agonists. When stimulated with their respective agonists, 
fluorescently tagged MOR and D2LR internalized and calcium release was observed following ligand-
mediated stimulation of cells expressing split nanoluciferase-tagged MOR and D2LR (Table S2). 
 
Figure 2. Localization analysis of the tagged receptors in live cells. HeLa cells were transiently 
transfected with pMOR-YFP (yellow) and pD2LR-mCherry (red) and subsequently (48 h post-
transfection), their localization was examined by epifluorescence microscopy. 
3.3. Analysis of MOR-D2LR Dimerization by BRET1 
To verify D2LR-MOR interaction in intact living cells, we used a noninvasive saturation BRET1 
assay. In this assay, HEK 293T cells were transfected with plasmids encoding a constant amount of 
MOR-RLuc or D2LR-RLuc as donor and increasing amounts of D2LR-YFP/MOR-YFP. For cells 
expressing MOR-RLuc, a control was also included where EYFP alone was the acceptor species. 
When the RLuc substrate, h-coelenterazine, is added, the energy generated from it excites YFP and 
emission fluorescence from it is recorded as a BRET signal. The BRET signal increased concomitantly 
with increasing amounts of the acceptor, until finally reaching saturation, giving rise to a hyperbolic 
curve, indicative of physical interaction between MOR and D2LR (Figure 3A,B). On the other hand, as 
exemplified for MOR-RLuc, the BRET signal was considerably smaller, increasing linearly with 
increasing amounts of EYFP in the condition where MOR-RLuc was coexpressed with EYFP as a 
negative control. The experiment was performed using both receptors as donor as well as acceptor, 
thus negating the possibility of an artifact introduced by the tags. 
 
Figure 3. Assessment of D2LR receptor dimerization with MOR using saturation bioluminescence 
resonance energy transfer (BRET1) assay. Saturation BRET1 assay was performed in HEK 293T cells 
transfected with a fixed amount of the donor plasmid: D2LR-RLuc (A) or MOR-RLuc (B) and 
increasing amounts of the acceptor plasmid: MOR-YFP (A)/D2LR-YFP (B)/EYFP (B). The data 
represent three–four independent experiments, fitted using nonlinear regression equation, assuming 
a single binding site. 
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3.4. Receptor Interaction Analysis by Functional Complementation of a Split Luciferase 
Next, we performed a functional complementation (NanoBiT®) assay to detect 
heterodimerization in living cells. This was done as the tags used in the BRET assay (luciferase and 
YFP) are both quite large, which may have an impact on the actual behavior of the receptors. To 
overcome this, tags based on a split nanoluciferase (NanoLuc) were utilized to study protein 
complementation. The receptors were C-terminally fused to the split fragments (LargeBiT, LgBiT 
{18kDa}, and SmallBiT, SmBiT {1kDa}) of the luminescence reporter, nanoluciferase. An equal 
amount of EGFP was cotransfected in every condition and the luminescence was normalized across 
the different set-ups. Interaction between MOR-LgBiT and D2LR-SmBiT results in functional 
complementation of nanoluciferase, which upon addition of the substrate furimazine results in a 
luminescent signal. As a negative control, HaloTag fused to SmBiT was used due to the ubiquitous 
expression of HaloTag inside the cell [39]. The signal produced due to MOR-LgBiT + D2LR-SmBiT was 
approximately 3.5-fold higher than the negative control MOR-LgBiT + HaloTag-SmBiT. Cells 
expressing only MOR-LgBiT or D2LR-LgBiT only yielded a background signal (Figure 4). 
Interestingly, when switching the nanoluc tags between both receptors (MOR-SmBiT + D2LR-LgBiT), 





D2LR D2LR / Halo-
Tag 
MOR MOR 
LgBiT MOR MOR MOR / D2LR D2LR D2LR / 
 
Figure 4. Analysis of D2LR interaction with MOR using NanoBiT®. HEK 293T cells were transfected 
with SmBiT and LgBiT-tagged receptor constructs as indicated above. The luminescent signal in cells 
cotransfected with D2LR fused to SmBiT and MOR fused to LgBiT was significantly higher (~3.5 fold) 
than the signal of the negative control, cells coexpressing Halotag-SmBiT and MOR-LgBiT. Three 
independent experiments were performed, and the results were expressed as mean ± SD (** p < 0.01). 
3.5. Assessment of MOR-D2LR Interaction Using FRET 
We further tested the MOR–D2LR interaction using FRET, with YFP serving as the donor species 
and mCherry as acceptor. HeLa cells were used instead of HEK 293T cells, as they are larger and 
better suited for microscopy purposes. For this, we cotransfected cells with MOR-YFP and either 
D2LR-mCherry or, as a negative control, mCherry-CAAX, whereby the CAAX motif is sufficient to 
target mCherry to the plasma membrane [40]. To obtain a comparable copy number of the mCherry 
acceptor molecules, a titration was performed with different concentrations of mCherry-CAAX 
versus D2LR-mCherry, and an optimized amount of mCherry-CAAX was used, which produced 
approximately the same intensity as D2LR-mCherry. The FRET signal in HeLa cells coexpressing 
MOR-YFP and D2LR-mCherry was significantly higher than that in control cells coexpressing MOR-
YFP and mCherry-CAAX (Figure 5). 




 mCherry CAAX D2LR 
YFP MOR MOR 
Figure 5. Analysis of D2LR dimerization with MOR using Fӧrster Resonance Energy Transfer (FRET). 
HeLa cells were transfected with pMOR-YFP, and either pD2LR-mCherry or pmCherry-CAAX. 
Donor–acceptor (DA)/ donor–donor (DD) ratios were determined under identical imaging conditions 
as described in the materials and methods section. Three independent experiments were performed, 
and results were expressed as mean ± SD (**p < 0.01). 
3.6. Mobility of MOR is Altered on the Plasma Membrane in the Presence of D2LR 
Given that the plasma membrane has a certain fluidity, the lateral mobility of membrane 
proteins is affected by their interaction with neighboring proteins [41–44]. Hence, FRAP would aid 
in understanding if mobility of MOR is altered upon interaction with D2LR at the plasma membrane. 
To address this, HeLa cells expressing MOR-YFP with and without D2LR-mCherry were used and 
membrane FRAP analysis was performed by bleaching the MOR-YFP protein at several defined 
regions on the plasma membrane, followed by monitoring of its recovery. Although the difference in 
half maximal recoveries between both conditions, i.e., MOR-YFP in the presence and absence of D2LR-
mCherry, did not reach statistical significance, it was observed that the time for half maximal 
recovery of MOR-YFP increased from ~77 s when D2LR-mCherry was not present to ~85 s when D2LR-
mCherry was coexpressed (Figure 6). Although this finding should be interpreted cautiously, this 
slight change in mobility of MOR upon coexpression of D2LR lends further support to the presence of 
an interaction between the two GPCRs. 
  
(A) (B) 
Figure 6. Analysis of interaction-mediated mobility change of MOR upon coexpression of D2LR by 
FRAP analysis. HeLa cells transfected with pMOR-YFP with and without pD2LR-mCherry were used 
for FRAP measurements, as described in the materials and methods section. (A) The plot depicts mean 
relative fluorescence intensity normalized to prebleach intensity as a function of time. The plot is an 
average for a population of approximately 50–60 cells from three–four independent experiments. The 
t1/2 value refers to the time taken for half maximal recovery after photobleaching. (B) Representative 
images of a FRAP experiment. Several regions on the plasma membrane were photobleached and 
FRAP was monitored for 9 min with 10 s interval between every image. 
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3.7. Heteromerization of MOR and D2LR Inhibits the Internalization of MOR after Activation 
Studies have shown that heteromers could act as a functional unit that is different from the 
monomers. Moreover, there have been enormous efforts to improve our understanding of the 
regulation of MOR by desensitization, internalization, dimerization, etc. With this in mind, we sought 
to examine the influence of interaction between MOR and D2LR on one of the most characteristic 
responses following activation of GPCRs, i.e., the internalization of MOR following agonist 
stimulation. For this, we used live cell imaging of HeLa cells transfected with pMOR-YFP with and 
without pD2LR-mCherry. Forty-eight hours post-transfection, cells were washed and imaged live for 
changes in the distribution of YFP protein over time. Upon stimulation with the MOR specific agonist, 
DAMGO (7 µM), a robust internalization of MOR-YFP, when present alone, could be recorded from 
the plasma membrane to the endomembranes within 10 min (Figure 7, black curve). The 
internalization was quantified by analyzing cytosolic intensity as a function of time (as described in 
the materials and methods section). The graphs depict the cytosolic intensity of a population of cells 
after stimulation, normalized to their basal condition in the absence of the agonist. In the presence of 
D2LR-mCherry, a marked reduction in the internalization of MOR upon stimulation with its agonist 
DAMGO was recorded, thus suggesting an influence of heterodimerization on the internalization of 
MOR. In all experiments, comparable expression intensities of MOR-YFP were recorded to avoid 
expression-related artifacts. In cells expressing only D2LR-EGFP that were stimulated with DAMGO, 
no D2LR-EGFP internalization could be observed, confirming that DAMGO does not act via the D2R 
(Table S2). 
 
Figure 7. Analysis of internalization of MOR upon stimulation with DAMGO in the presence or 
absence of D2LR by fluorescence live cell imaging. (A) HeLa cells transfected with pMOR-YFP with or 
without pD2LR-mCherry were used for fluorescence imaging as described in the materials and 
methods section. The images were captured for 1 h, with 10 s between successive images. At the 10th 
frame (100 s), DAMGO (7 µM) was injected using a syringe pump. (B) The plot depicts cytosolic 
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fluorescence intensity normalized to the intensity before stimulation as a function of time. 
Approximately 50–60 cells were analyzed for each system. The results were expressed as mean ± 
standard error of mean (SEM) (*p < 0.05). 
4. Discussion 
Several studies have demonstrated the presence of homo-, hetero-, and even higher order 
oligomers of GPCRs in cells and in tissues [45,46], but the functional relevance of these interactions 
has remained unexplored in many instances. In a study performed by Dai et al. [35], an increased 
expression of neuronal D2R in the spinal dorsal horns of mice was observed upon chronic treatment 
with morphine. Immunofluorescence studies revealed that D2R colocalized with MOR in the spinal 
cords of mice, and both receptors could be coimmunoprecipitated. Upon chronic morphine 
treatment, this interaction increased, while blockade of D2R with sulpiride disrupted the interaction 
and also attenuated morphine tolerance, suggesting that increased MOR–D2R interaction may play a 
role in chronic morphine tolerance. Our study is in agreement with the findings of Dai et al. [35] and 
lends further support for the possible interaction between MOR and D2R, as supported by various 
approaches such as co-IP, BRET1, NanoBiT®, and FRET. Furthermore, we observed an influence of 
dimerization between D2LR and MOR on DAMGO-mediated internalization of MOR. 
The mu opioid receptor is of significant importance due to its pivotal role in mediating the effects 
of analgesics like morphine and owing to its undesirable side effects including addiction, 
dependence, etc. In 1999, Jordan et al. [47], showed for the first time that another member of the 
opioid receptor family, the delta opioid receptor (DOR) could heterodimerize with the kappa opioid 
receptor. Since then, several reports have been published on the dimerization of MOR with DOR 
[31,48,49], and with other GPCRs [32,50–52], thereby starting a new dimension in the field of 
analgesia. On one hand, efforts are constantly being dedicated to developing new ligands that are 
agonists of MOR, but do not have the undesired side effects. On the other hand, fundamental research 
is being carried out to understand the signaling of MOR, so that it could be modulated with ligands. 
E.g., Qian et al. [53] recently reported on the usage of heterobivalent ligands based on agonists and 
antagonists of MOR and D2-likeR to act as pharmacological tools that should allow us to gain more 
insight into heteromers. 
In the present study, we have obtained strong evidence for the presence of D2R and MOR 
heterocomplexes, using two different cell lines and a variety of chimeric receptors fused to different 
tags for studying protein–protein interactions. All the evaluated chimeric receptors were found to be 
active through their ability to initiate calcium signaling [17] or by their capacity to internalize upon 
stimulation with an agonist. 
Co-IP was used to check the heterodimerization and the results indicated the existence of MOR–
D2R heterocomplexes in cotransfected cells (Figure 1). To address the question about specificity of the 
interaction, lysates of single receptor transfected cells were mixed, and the lack of co-IP indicated that 
the receptors physically interact with each other within a given cell (Figure S1). 
To clearly illuminate the nature of the dimerization, we used an array of techniques using living 
cells expressing receptor fusion constructs, one such technique being BRET1. We observed strong 
BRET signals between D2R and MOR, implying that the two receptors are within a distance of 10 nm, 
and the experiment was performed in both ways, to strengthen our hypothesis. Since overexpression 
of receptors may lead to random collisions and consequently produce a false signal, we have also 
included a negative control wherein the same saturation BRET1 assay was performed with receptor-
RLuc and increasing concentrations of EYFP. The linear nature of the negative control, as compared 
to a hyperbolic curve obtained with co-expressed receptors, showed that the receptors interact with 
each other (Figure 3). 
A recently developed luminescence complementation-based approach, developed by Promega, 
known as “Nanoluciferase Binary Technology”/NanoBiT®, was also used to study the interaction 
between D2LR and MOR. The signal obtained for the interaction (D2LR-SmBiT + MOR-LgBiT) was 
approximately 3.5-fold higher than that of the negative control (Halotag-SmBiT + MOR-LgBiT) 
(Figure 4). Also, the background signal obtained with receptor-LgBiT fusions alone was low. An 
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interesting observation made here was that when the interaction was studied with the tags switched 
(MOR-SmBiT + D2LR-LgBiT), only a low signal was obtained, indicating that a specific configuration 
seems to be required for functional complementation of the luminescent protein. More specifically, 
the configuration in which SmBiT and LgBiT are fused to the C-termini of MOR and D2LR, 
respectively, may not allow functional complementation of the split fragments of nanoluciferase 
because of sterical hindrance or misorientation. 
We also evaluated the formation of the heterodimer in another cell line, HeLa, using FRET. 
Different variants of FRET have been used to study GPCR dimerization. Recently, Niewiarowska-
Sendo et al. [54] reported the formation of a functional dimer between the bradykinin receptor and 
the dopamine D2LR using fluorescence lifetime imaging microscopy-based fluorescence resonance 
energy transfer (FLIM-FRET) technique. In our experiments, in which we chose MOR-YFP as the 
donor and D2LR-mCherry as the acceptor, a significantly higher signal was obtained than in the 
negative control, acceptor mCherry-CAAX, providing a strong evidence for dimer formation (Figure 
5). 
In 2009, Dorsch et al. [55] applied dual color FRAP to answer the question on GPCR 
oligomerization. With the help of polyclonal antibodies against YFP, they immobilized the YFP-
tagged receptor, while the other interacting partner was tagged to CFP. By means of dual color FRAP, 
they observed that the β1-adrenergic receptor (β1-AR) formed monomers that are unstable, in contrast 
to the β2-adrenergic receptor (β2-AR), which formed stable higher-order oligomers. The dimerization 
event in Class A GPCRs is more complicated than in other classes since there are multiple interfaces 
and owing to the fact that the interactions are transient in nature [56]. For D2R–D2R interactions, this 
was recently supported by modelling studies [23] and by studies indicating a dimer lifetime of only 
68 ms [57,58]. In our study, we performed FRAP by bleaching MOR-YFP at several regions on the 
plasma membrane with or without coexpressed D2LR-mCherry. Although statistically not significant, 
a slight decrease in mobility of MOR-YFP in the presence of D2LR-mCherry was found, which 
supports the hypothesis that the two GPCRs interact with each other (Figure 6). 
In recent years, there have been substantial efforts to understand the molecular regulation of 
desensitization and internalization of MOR [4,59–63]. Studies have shown that the MOR agonists 
fentanyl and DAMGO are more efficacious at recruiting β-arrestin to the receptor [64,65], 
subsequently causing internalization of the receptor, when compared to morphine, which shows 
delayed recruitment of β-arrestin and a slower internalization [66–68]. It is the recruitment of β-
arrestin that has been associated with the unwanted effects of opioids [11,69–71]. 
With this in mind, we sought to study the effect of heterodimerization of MOR-D2LR on the 
internalization characteristics of MOR. For this, time-lapse imaging is one of the best suited 
techniques to understand the spatial and temporal aspects of internalization of the receptor. Here, 
the dynamics of MOR-YFP internalization were studied in HeLa cells, with and without co-
expression of D2LR-mCherry. MOR-YFP showed robust internalization when stimulated with 
DAMGO, in agreement with the literature. Upon co-expression of D2LR, and when stimulated with 
DAMGO, we noticed that the internalization of MOR-YFP slowed down (Figure 7), thus suggesting 
that the heterodimerization may have a role in modulating internalization of the interacting partner. 
In a recent study by Dai et al. [21], it was demonstrated that l-CDL could attenuate morphine 
tolerance in rats with chronic bone cancer pain. This compound proved to be an antagonist of D2R as 
it inhibited dopamine-induced calcium release in CHO-K1 cells expressing D2R. A similar effect, as 
observed in their previous study [35], was noticed upon coadministration of l-CDL with morphine, 
and the effect was reversed upon addition of quinpirole, a D2R agonist in mice. The findings were 
reconfirmed when they observed diminished tolerance upon administration of D2R siRNA, which 
silenced the D2R gene. Chronic morphine tolerance upregulated the expression of β-arrestin 2, which 
decreased both upon addition of D2R-siRNA and l-CDL. Both the phosphoinositide 3-kinase 
(PI3K)/Akt pathway and the mitogen-activated protein kinase (MAPK) pathway are involved in the 
development of morphine tolerance, and both D2R siRNA and l-CDL reduced the levels of key 
phosphorylated proteins of both pathways. 
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Another study provided evidence for an enhanced antinociceptive effect of the MOR agonist 
DAMGO, when coadministered with quinpirole [22]. In intact animals, this synergistic effect of 
antinociception was only seen in mechanonociceptive tests. However, in neuropathic or 
inflammatory models of pain, quinpirole enhanced antinociception in both mechanonociceptive and 
thermonociceptive tests. Also, the enhanced antinociceptive effect observed by coadministration of 
subeffective doses of DAMGO and quinpirole was driven by D2R because this effect was abolished 
by administration of the highly selective D2-like receptor antagonist raclopride. 
Although these studies clearly suggest an interplay between D2R and MOR, the link between 
D2R and opioid analgesia, as well as tolerance, still remains unclear as there are reports for both D2R 
antagonists and D2R agonists to attenuate morphine tolerance [21,35]. 
5. Conclusions 
The data presented here and obtained using a combination of biochemical techniques, co-IP, 
BRET1, NanoBiT®, and FRET, shed light on the heterodimerization between MOR and D2R. In 
addition, the change in internalization of MOR in the presence of D2R suggests that these receptors 
functionally interact with each other. Future studies to evaluate the influence of heterodimerization 
of MOR on G protein signaling following receptor activation may lead to a better understanding on 
whether the antinociceptive effects of MOR agonists are affected. Based on current findings and 
future experiments, novel therapies targeting the heterodimers could be designed. Taken together, 
this study improves our understanding of the complex cellular network that influences signaling 
through a GPCR. Much remains to be explored about the kind of downstream signaling that is altered 
due to the heterodimerization process requiring following research, using both in cellulo as well as 
in vivo approaches. 
Supplementary Materials: Supplementary data associated with this article can be found at 
www.mdpi.com/xxx/s1. Figure S1: Analysis of D2SR receptor dimerization with MOR using co-
immunoprecipitation. Table S1: List of primers used in the study. Table S2: Overview of the functionality of 
constructs used in the study using various assays and agonists. 
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